GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TheraCryf PLC (FRA:8EV) » Definitions » Common Stock

TheraCryf (FRA:8EV) Common Stock : €1.27 Mil (As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is TheraCryf Common Stock?

TheraCryf's quarterly common stock increased from Sep. 2023 (€0.80 Mil) to Mar. 2024 (€0.80 Mil) and increased from Mar. 2024 (€0.80 Mil) to Sep. 2024 (€1.27 Mil).

TheraCryf's annual common stock declined from Mar. 2022 (€0.82 Mil) to Mar. 2023 (€0.78 Mil) but then increased from Mar. 2023 (€0.78 Mil) to Mar. 2024 (€0.80 Mil).


TheraCryf Common Stock Historical Data

The historical data trend for TheraCryf's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TheraCryf Common Stock Chart

TheraCryf Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.37 0.80 0.82 0.78 0.80

TheraCryf Semi-Annual Data
Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.79 0.78 0.80 0.80 1.27

TheraCryf Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


TheraCryf Business Description

Traded in Other Exchanges
Address
Congleton Road, Alderley Park, Nether Alderley, Cheshire, GBR, SK10 4TG
TheraCryf PLC is a clinical-stage biotechnology company focused on profitable segments in oncology and neuropsychiatry. The company's lead clinical asset, SFX-01 is a patented form of delivering sulforaphane, which could be used in the treatment of a number of cancers, neurodevelopmental disorders, and other diseases.

TheraCryf Headlines

No Headlines